Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is among the Most Volatile Stocks.
On February 6, 2026, TD Cowen upgraded Adaptive Biotechnologies Corporation’s price target to $21 from $20 while keeping a Buy rating, citing a Q4 beat and an improved outlook. TD Cowen said that community adoption, new indications, pharma guidelines, EMR integrations, and a shift to blood-based testing were major driving factors.
On February 6, 2026, BTIG maintained a Buy rating on Adaptive Biotechnologies Corporation and increased its price target from $21 to $22, following Q4 earnings. BTIG describes the company as a leading growth story in specialty labs.
On February 6, 2026, JPMorgan boosted Adaptive Biotechnologies Corporation’s price objective from $20 to $21 while retaining an Overweight rating, citing the Q4 report as strong. The corporation anticipates FY26 MRD business revenue of $255 million to $265 million, with total operating expenses, including cost of revenue, ranging from $350 million to $360 million.
Mila Supinskaya Glashchenko/Shutterstock.com
Adaptive Biotechnologies Corporation develops an immune medicine platform. The company provides immunoSEQ, clonoSEQ, cellular treatment, and vaccinations.
READ NEXT: 20 Best Performing Stocks in 2025 and 12 Best Food Stocks to Buy in 2026.
